Biocon Ltd News

Biocon subsidiary secures permission to launch eye medicine Yesafili in US

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says

Biocon Biologics signs deal, gets market entry for Yesafili in US by 2026

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement. The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added. The terms of the settlement are confidential, it stated. "This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality ..

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio

Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels

Biocon gains 2% on US FDA nod for ANDA Norepinephrine Bitartrate Injection

The company's subsidiary has received approval from the US Food and Drug Administration (US FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial

Did FIIs cover F&O short positions in Wednesday's rally? Data says this

Derivatives market data shows that open bets in Nifty and Bank Nifty futures declined up to 8% yesterday; with FIIs covering some short bets, however they still hold significant shorts positions.

Here's why Biocon share price popped 3% in trade on March 5; details here

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Biocon Biologics investors are more confident after revenue growth: Mittal

There is market share gain compared to last year. Any biosimilar might be able to take on a four-five or six player market, said Siddharth Mittal, CEO and MD, Biocon

Biocon Biologics plans IPO for biosimilars business by Mar 2026: CEO

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public

Here's why Biocon share price gained 4% despite fall in profits in Q3

Biocon share price gained 3.82 per cent at Rs 370.80 a piece on the BSE in Friday's intraday trade

Biocon Q3 results: Net profit at Rs 25 cr, revenue at Rs 3,821 crore

It also reported a profit before tax (PBT) of Rs 155.9 crore, down 80.8 per cent in Q3FY25

Biocon gains 3% after board to mull raising funds via commercial papers

Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday's intraday trade

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech instruments

Ajit Mishra of Religare Broking picks Biocon, Marico as stocks to buy today

Stocks to Buy Today: Ajit Mishra of Religare Broking suggests buying Biocon shares and Marico shares. He also suggests shorting Asian Paints shares

Biocon, Marico among 5 mid-, small-cap stocks holding fort in a weak market

The overall market trend has been negative with over 60% of the Nifty Mid- and Small-Cap stocks now trading below the long-term moving averages; however, these 5 stocks continue to buck the trend.

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions